FindTrial
Sign In

SNF472

DRUG2 trials

Sponsors

Sanifit Therapeutics S. A.

Conditions

Calcific Uremic ArteriolopathyCalcifications, VascularCalciphylaxisCardiovascular AbnormalitiesCardiovascular DiseasesCoronary Artery CalcificationESRDEndstage Renal Disease

Phase 2

Phase 2 Study With SNF472 in Calciphylaxis Patients
CompletedNCT02790073
Sanifit Therapeutics S. A.Calcific Uremic Arteriolopathy, Calciphylaxis
Start: 2016-05-31End: 2017-11-15Updated: 2019-08-28
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
CompletedNCT02966028
Sanifit Therapeutics S. A.Calcifications, Vascular, Cardiovascular Abnormalities, Cardiovascular Diseases +3
Start: 2016-11-30End: 2019-09-30Updated: 2021-04-15

Related Papers

Hexasodium fytate exposure-response correlations in a randomized, placebo-controlled study of patients on dialysis with cardiovascular calcification
Frontiers in Pharmacology2024-02-07
Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis
Clinical Journal of the American Society of Nephrology2021-04-0717 citations
Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis
Circulation2019-11-11135 citations